Asenapine Transdermal Patch Matrix for Sustained Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asenapine administration methods, particularly sublingual tablets, suffer from low bioavailability, unpleasant taste, patient compliance issues, and skin irritation, with no effective transdermal therapeutic systems (TTS) available for convenient and prolonged delivery.
Innovation Solution
A matrix-type TTS comprising a self-adhesive layer structure with asenapine in the form of a free base and polysiloxanes or polyisobutylenes, optionally with additional excipients, designed for transdermal administration, providing a permeation rate sufficient for therapeutic doses over 20 hours with reduced fluctuation and minimal skin irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sublingual tablets are used for asenapine administration, then bioavailability is improved by avoiding first-pass metabolism, but patient compliance deteriorates due to unpleasant taste and administration inconvenience
Solution Approach 1:
The patent replaces the sublingual mechanical administration route with a transdermal delivery system. The TTS uses passive diffusion through the skin to deliver asenapine directly into systemic circulation, eliminating the need for sublingual placement and avoiding the unpleasant taste associated with sublingual tablets while maintaining high bioavailability
Solution Approach 2:
The patent employs a flexible transdermal patch structure with a polymer matrix that contains asenapine. The thin film design allows close contact with the skin surface, enabling sustained drug release through the stratum corneum while providing a convenient, tasteless, and compliant-friendly administration method
2Ease of operation
If transdermal delivery of asenapine is implemented, then patient compliance and convenience are improved, but permeation rate is insufficient to achieve therapeutically effective doses
Solution Approach 1:
The patent optimizes the permeation rate by carefully controlling the polymer matrix composition, asenapine concentration (2-10% w/w), and layer structure. The formulation achieves a permeation rate of at least 0.5 µg/cm²/h, which is sufficient to deliver therapeutically effective doses while maintaining patient compliance through convenient transdermal application
Solution Approach 2:
The patent uses a composite polymer matrix system combining hydrophobic and hydrophilic polymers to optimize asenapine release and permeation. The composite material structure enhances drug diffusion through the skin while maintaining structural integrity and controlled release kinetics
3Duration of action of moving object
If transdermal therapeutic system is designed for prolonged delivery, then duration of action is improved for once-daily application, but skin irritation increases
Solution Approach 1:
The patent achieves prolonged duration of action (at least 20 hours) by optimizing the polymer matrix composition and asenapine loading. The controlled release mechanism maintains therapeutic plasma concentrations over 20 hours while using skin-friendly polymer materials that minimize irritation and enhance patient comfort for once-daily application
Solution Approach 2:
The patent employs biocompatible and inert polymer materials in the transdermal system that do not provoke significant skin irritation. The polymer matrix creates a controlled, non-irritating environment for sustained drug release, enabling prolonged duration of action without compromising skin tolerance
4Device complexity
If passive transport mechanism is used in TTS, then device complexity is reduced compared to active transportation, but permeation rate and active ingredient utilization deteriorate
Solution Approach 1:
The patent achieves sufficient permeation rate through passive transport by optimizing the polymer matrix composition, asenapine concentration, and layer structure. The formulation parameters are carefully tuned to maximize diffusion-driven delivery, achieving therapeutically effective permeation rates without the complexity of active transport mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TTS achieves therapeutically effective asenapine delivery for at least 20 hours with improved bioavailability, reduced plasma concentration fluctuations, and minimal skin irritation, suitable for once-daily application, addressing the limitations of sublingual administration.
Implementation Method 1
passive transport of asenapine would be desirable. Passive transport of active agents from a transdermal therapeutic system (TTS) through the skin makes use of the driving force based on the concentration gradient between the concentration of active agent in the transdermal system and on the outer surface of the skin and the concentration in the blood stream
Data Source
AI summary
The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising: A) a backing layer; B) an asenapine-containing layer comprising: 1. asenapine in the form of the free base; and 2. a polymer selected from the group consisting of polysiloxanes and polyisobutylenes in an amount of more than 50% by weight based on the total weight of the asenapine-containing layer; and C) optionally an additional skin contact layer.